https://www.selleckchem.com/pr....oducts/Gefitinib.htm
Median PFS was 2.2 months (95% CI 0.8-7.4) with monotherapy and 5.4 months (95% CI 2.3-7.9) with the combination; median OS was 7.8 months (95% CI 4.4-18.5) and 33.7 months (95% CI 15.4-not evaluable), respectively. Promising OS benefit was observed in combination-treated patients who had received prior docetaxel (16.0 months, 95% CI 6.4-34.6; n = 2 and those with visceral metastasis (16.4 months, 95% CI 4.0-not evaluable; n = 11). All patients had ≥1 treatment-related adverse event, mostly grade 1/2 manageable events. No additive t
Like
Comment
Share
